NICE provisionally approves Almirall's ILUMETRI®▼ (tildrakizumab), as a cost effective option for adults with moderate-to-severe plaque psoriasis
2019-03-08 · Almirall, S.A. · original almirall.com ↗
Final NICE approval is expected in April 2019 From this date, dermatologists in the UK will have an additional biologic treatment option and suitable patients can be considered for treatment with ILUMETRI ® (tildrakizumab) Tildrakizumab is a high-affinity humanized monoclonal antibody that inhibits the p19 subunit of IL-23 1 , that has demonstrated lasting efficacy and safety through 3 years according to the positive results of a pooled analysis 2 of two phase III clinical trials Tildrakizumab was approved by the European Commission in September 2018, is already available in Germany and is due to be marketed in all EU Member states
The release as fetched from its publisher. almirall.com ↗